Trial Profile
A Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multiple Dose, Multicenter Study in Subjects With Mild to Moderate Dementia of the Alzheimer's Type to Evaluate the Safety and Tolerability of Two 10-Week Dose Regimens of Orally-Administered PF-04494700
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Azeliragon (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Pfizer
- 08 Feb 2010 Endpoint methodology added (where possible).
- 12 May 2009 Actual end date (Jun 2006) added as reported as reported by ClinicalTrials.gov.
- 12 May 2009 Official Title amended as reported by ClinicalTrials.gov.